Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable bod.

Teva's New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a Phase 3 study evaluating the efficacy and safety of AJOVY for the prevention of migraine in adult Chinese patients. In the study, AJOVY achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo. Al.

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will b.

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

General Motors

Pfizer

One estimate suggests artificial intelligence (AI) can add close to $16 trillion to the global economy by the turn of the decade. Nvidia is rife with red flags, which may have been the catalyst that encouraged three top-tier billionaire asset managers to reduce their respective positions in the AI kingpin.

Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of eight studies from its LAI schizophrenia research program, including data evaluating UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults. The data were presented at the 2024 Congress of the Schizophrenia In.

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024

TEL AVIV, Israel, & MADRID--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced they have entered a strategic licensing agreement for a biosimilar candidate currently in development for the treatment of multiple oncology indications. Biosimilars show promising potential in providing more cost-effective alte.

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Realty Income Corp

Block

Although the Dow Jones, S&P 500, and Nasdaq Composite have rocketed to fresh all-time highs, opportunistic long-term investors can still uncover amazing deals. Many online brokers have removed barriers that had previously kept retail investors on the sidelines.

3 No-Brainer Stocks to Buy With $600 Right Now

Viatris

Teva Pharmaceutical and Viatris convinced a U.S. appeals court on Monday to revive their challenges to a patent covering a blockbuster Johnson & Johnson schizophrenia drug, giving them a new chance to clear a path to launch cheaper generic versions of the medicine.

Teva, Viatris win new chance to challenge J&J schizophrenia drug patent

CASTLEFORD, England & LONDON--(BUSINESS WIRE)--Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicines. Under the agreement, Closed Loop Medicine – a leading TechBio company – and pharmaceutical company, Teva UK, will investigate opportunities to use Closed Loop Medicine's proprietary software as a medical device (SaMD) technology platform which aims to advance the development of personalised medicines, improve dru.

Teva UK and Closed Loop Medicine Announce Strategic Partnership to Advance Development of Personalised Medicines

Teva Pharmaceutical is deeply undervalued, trading at a 77% discount per my calculations, and the new CEO's turnaround plan looks promising. Teva is an Israeli pharmaceutical company focused on affordable generic medicine, with a strong presence in North America.

Teva Pharmaceutical Industries: Potential Outweighs Concerns

Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities

Teva Pharmaceutical (NYSE: TEVA ) stock is getting a boost on Monday after a partner company received approval from the Food and Drug Administration (FDA). This approval allows for Alvotech's (NASDAQ: ALVO ) SIMLANDI injection to be used as an interchangeable biosimilar to Humira.

TEVA Stock Pops 4% as Teva Receives FDA Approval

SHANGHAI & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today announced it formed a partnership for the marketing and distribution of Teva's AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington's disease (HD) and tardive dyskinesia (TD) in adults. The par.

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.

6 reasons to buy Teva Pharmaceuticals stock sooner than later

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced positive safety, tolerability, and pharmacokinetic data for its anti-TL1A (TEV-'574) asset, a potentially best-in-class human IgG1 monoclonal antibody that targets the tumor necrosis factor (TNF)-like ligand 1A (TL1A) and is designed to offer both anti-inflammatory and anti-fibrotic effects.1-3 The data show the rapid and sust.

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting

Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard Francis said on Tuesday.

Teva Pharm to stay as unified generics, branded drugmaker, CEO says

Teva Pharmaceutical has experienced a significant downturn in the last decade but has recently shown signs of recovery. The company has stabilized its operating income of around $3 billion for the past five years, but its large debt load is holding back shareholder value. Teva's revenue growth in 2023, driven by drugs like Austedo and Ajovy, indicates a potential turnaround, but the company still faces challenges with debt and interest payments.

A Review Of Teva's Prospects

TORONTO--(BUSINESS WIRE)--Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry.

Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

TEVA Q4 Earnings and Revenues Surpass Estimates, Stock Up

MONTPELLIER, France--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release About UZEDY During the Q4 2023 earnings call held today by Teva Pharmaceutical Industries Ltd., President and CEO Richard Francis stated that he expects a strong uptake and significant growth for UZEDY in 2024. He notably provided the annual revenue guidance for UZEDY, projecting approximately $80 million for 2024. This revenue projection is aligned with MedinCell's forecasted earnings from UZE.

MedinCell's Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)

Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teva Pharmaceutical Industries Ltd. (TEVA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Teva stock dipped early Wednesday after the drugmaker issued light earnings guidance, at the midpoint, despite a strong quarterly report.

Teva Sinks On Lackluster Profit Outlook Despite Walloping Quarterly Projections

TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2023. Q4 2023 and Full Year 2023 Highlights:   Q4 2023 FY 2023 Revenues   $4.5 billion $15.8 billion GAAP diluted earnings (loss) per share   $0.41 $(0.50) Non-GAAP diluted EPS   $1.00 $2.56 Cash flow generated from operating activities   $1,184 million $1,368 million Free cash flow   $1,486 million $2,387 million Mr. Richard Francis.

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.

News for Teva Pharmaceutical Stock (TEVA)